Engineering The Future Of Antibody-Drug Conjugates

Antibody-drug conjugates are reshaping cancer treatment, but their success depends on more than targeted biology alone. Upstream bioprocessing now plays a defining role in whether ADC programs scale efficiently, maintain product quality, and stay on track for clinical and commercial milestones. Media and feed optimization, cell-line selection, and control of critical quality attributes all influence conjugation efficiency, manufacturability, and regulatory readiness long before payload attachment begins. As ADCs move into earlier lines of therapy and larger patient populations, developers are turning to predictive modeling, real-time monitoring, and smarter supplier partnerships to reduce variability and improve robustness.

Gain insight into how biology, data, and process strategy are converging to shape the next wave of ADC development.